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Abstract
Objective To determine whether statin therapy influences
the efficacy of thrombin inhibitor bivalirudin or unfrac-
tionated heparin (UFH) during PCI.
Setting and patients The post-hoc analysis of the ISAR-
REACT 3 Trial included 4,570 patients: 3,106 patients
were on statin therapy and 1,464 patients were not on statin
therapy at the time of PCI procedure.
Main outcome measures The primary outcome of this
analysis was the 30-day composite of death, myocardial
infarction, target vessel revascularization (TVR) or major
bleeding.
Results The primary outcome occurred in 7.9% patients
(n = 246) in the statin group versus 9.8% (n = 143) in the
non-statin group (P = 0.036). There was an interaction in
univariate (P = 0.028) and multivariable (P = 0.026)
analysis between pre-PCI statin therapy and the type of
antithrombotic therapy regarding myocardial infarction. In
the statin group, bivalirudin significantly reduced the
incidence of major bleeding (2.6 vs. 4.3%, P = 0.013) with
no significant difference in the incidence of myocardial
infarction (4.9 vs. 5.2%; P = 0.73) compared with UFH. In
the non-statin group, bivalirudin was inferior to UFH
regarding the incidence of myocardial infarction (7.1 vs.
4.1%, P = 0.013), yet major bleeding remained lower
among bivalirudin-treated patients (4.0 vs. 5.2%,
P = 0.25).
Conclusion This post-hoc analysis suggests the existence
of an interaction between statin therapy before PCI and
antithrombotic therapy during PCI. Patients receiving
bivalirudin therapy at the time of PCI showed less peri-
procedural myocardial infarction when on pre-PCI statin
therapy which has to be investigated in further studies.
Keywords Antithrombotics  Statins  Heparin 
Bivalirudin  Stents
Introduction
Both ischemic and bleeding complications of percutaneous
coronary interventions (PCI) influence 1-year mortality in
patients undergoing PCI [1]. Accordingly, several newer
antithrombotic agents have been compared with unfrac-
tionated heparin (UFH) in an attempt to reduce these
adverse clinical events. Bivalirudin, a direct thrombin
inhibitor, has been shown to significantly reduce bleeding
in a wide clinical spectrum of coronary artery disease
patients undergoing PCI compared to UFH, with or without
adjunctive glycoprotein IIb/IIIa inhibitor adminstration
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[2–5]. Nevertheless, there has been a trend toward more
frequent ischemic complications—mainly procedural
myocardial infarction—with bivalirudin monotherapy,
independent of clinical syndrome acuity, although greater,
in some studies, in patients with acute coronary syndromes
not treated with a thienopyridine [6]. Moreover, among
patients treated by primary PCI for acute myocardial
infarction, there was an increased frequency of acute stent
thrombosis in the 24 h following the PCI procedure,
however, the reinfarction rates were similar between biv-
alirudin and heparin plus glycoprotein IIb/IIIa inhibitor [4].
These apparently different effects of UFH and bivalirudin
on the risk of myocardial infarction and bleeding have
produced a significant reduction in net clinical outcomes
with bivalirudin (the sum of ischemic and bleeding events)
[2–4]. However, in the Intracoronary Stenting and Anti-
thrombotic Regimen: Rapid Early Action for Coronary
Treatment 3 (ISAR-REACT 3) Trial in which only bio-
marker negative patients were enrolled, the net clinical
outcomes were similar with the two antithrombins,
although bivalirudin did also reduce measures of bleeding
compared to heparin alone [5].
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors or statins are a cornerstone
therapy in the primary and secondary prevention strategies
of coronary artery disease. It has recently been suggested
that statins may reduce procedural myocardial infarction
following PCI [7–10]. Their positive influence is hypoth-
esized to result from not only lipid lowering but also other,
non-lipid lowering (pleiotropic) effects, including anti-
inflammatory, antithrombotic and antiproliferative effects
[11–15]. Therefore, an interaction with antithrombotic
agents given during PCI is plausible in patients on statins.
In this study, a post-hoc analysis of the ISAR-REACT 3
trial, we sought to: (1) investigate the impact of pre-PCI
statin therapy on the 30-day clinical outcome of patients
enrolled in ISAR-REACT 3, and (2) to determine whether
there is an interaction between pre-PCI statin therapy and
antithrombotic agents (bivalirudin or UFH) in terms of
ischemic events within 30 days, and in-hospital major
bleeding.
Methods
The Intracoronary Stenting and Antithrombotic Regimen:
Rapid Early Action for Coronary Treatment 3 (ISAR-
REACT 3) trial included 4,570 biomarker negative patients
with coronary artery disease in whom PCI was planned
enrolled between September 2005 and January 2008.
Details of the trial design, patient eligibility and laboratory
measurements have been reported before [5]. In brief, all
patients were pretreated with 325–500 mg aspirin and
600 mg of loading dose of clopidogrel at least 2 h before
the PCI procedure. Before the guide wire had crossed the
lesion, patients were randomized to receive a 0.75 mg/kg
bolus of bivalirudin followed by an infusion of 1.75 mg/kg/h
for the duration of procedure (bivalirudin group; n = 2,289
patients) or 140 U/kg bolus of UFH followed by placebo
infusion for the duration of the procedure (heparin group;
n = 2,281 patients). Double blinding was achieved by use of
identically appearing vials in both study groups. Post-pro-
cedural therapy included daily aspirin, 80–325 mg indefi-
nitely, clopidogrel, 75–150 mg/day until discharge but no
longer than 3 days followed by 75 mg/day for at least
1 month (bare-metal stents) or at least 6 months (drug-elut-
ing stents) and other cardiac medications prescribed by the
patient’s physician. Electrocardiographic examinations and
laboratory measurements including cardiac enzymes,
hemoglobin and platelet count were performed every 8 h for
the first 24 h after the PCI procedure and daily, until
discharge.
The primary outcome of this post-hoc analysis was the
combined incidence of death from any cause, myocardial
infarction, urgent target vessel revascularization (coronary
bypass surgery or PCI) due to myocardial ischemia within
30 days after randomization, or major bleeding during the
index hospitalization (the composite quadruple endpoint)
in patients on statins at time of randomization (statin
group) and those not on statins (non-statin group) treated
by bivalirudin or UFH. The definition of major bleeding
used was the same as was used in the Randomized Eval-
uation in PCI Linking Angiomax to Reduced Clinical
Events (REPLACE-2) trial [2]: intracranial, intraocular, or
retroperitoneal hemorrhage, clinically overt blood loss
resulting in a decrease in hemoglobin of more than 3 g/dl,
any decrease in hemoglobin of more than 4 g/dl, or
transfusion of 2 or more units of packed red blood cells or
whole blood. The definition of myocardial infarction
included the development of pathologic Q waves (C30 ms
in duration and C0.1 mV in depth) in C2 contiguous pre-
cordial leads or C2 adjacent limb leads, or elevation of
creatine kinase (CK) MB isoenzyme (or total CK if CK-
MB not available) C2 times the upper limit of normal. A
phone interview was performed 30 days after the index
PCI. Patients with cardiac complaints within the 30-day
interval underwent a complete clinical, electrocardio-
graphic, and laboratory evaluation.
The data are presented as mean ± SD or percentages.
Categorical data were compared with the Chi-squared test,
or Fisher’s exact test when expected cell values were \5.
Continuous data were compared with two-tailed unpaired
t test. An interaction test between the type of antithrom-
botic therapy (bivalirudin or UFH) and statin use at the
time of enrollment regarding the clinical outcome was
performed. Multivariable analysis (the Cox proportional
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hazards model) was used to identify independent risk fac-
tors associated with 30-day myocardial infarction. Vari-
ables entered into the model were age, sex, statin therapy at
randomization, diabetes mellitus, arterial hypertension,
smoking, hypercholesterolemia, unstable angina, mul-
tivessel disease, prior myocardial infarction, antithrom-
botic agent and statin–antithrombotic agent interaction.
Analysis was performed with the S-plus statistical package
(S-PLUS, Insightful Corp, Seattle, Wash). A probability
value \0.05 was considered to indicate statistical
significance.
Results
The study included 4,570 patients: at the time of random-
ization and the index PCI procedure, 3,106 patients were
on statins (1,555 patients randomized to bivalirudin and
1,551 patients randomized to UFH) and 1,464 patients were
not (734 patients randomized to bivalirudin and 730
patients randomized to UFH). The baseline clinical char-
acteristics of patients on and not on statins are shown in
Table 1. Patients in the statin group had more adverse
cardiovascular risk factors than patients in the non-statin
group. Table 2 shows the angiographic and procedural data
for all patients for each lesion treated. Table 3 shows main
concomitant drug therapy recorded at admission.
The composite quadruple endpoint occurred less fre-
quently in the statin group than the non-statin group (7.9
vs. 9.8%, P = 0.036). There were no significant differ-
ences in the individual components of the primary out-
come; a trend toward a lower incidence of major bleeding
among patients of the statin group was observed (3.4 vs.
4.6%, P = 0.062). There was an interaction of borderline
significance (P = 0.05) between statin use and antithrom-
botic agent regarding the primary outcome which became
significant (P = 0.024) regarding the composite of death,
myocardial infarction or urgent target vessel revasculari-
zation. For individual components of the composite out-
come, there was an interaction (P = 0.028) between statin
therapy and antithrombotic agent regarding the incidence
of myocardial infarction. The clinical outcomes of statin
and non-statin groups are shown in Table 4.
As a result of the observed interaction(s), the primary
outcome and its individual components were separately
investigated according to bivalirudin or heparin in the
statin and non-statin groups. The results are shown in
Table 5. It can be seen in the statin group that bivalirudin
therapy resulted in significantly less major bleeding (2.6 vs.
4.3%, P = 0.013) with no significant difference in the
Table 1 Baseline
characteristics of the study
population
Data are mean ± SD or number
of patients (with percents in
parentheses)
Characteristic On statins
(n = 3,106)
Not on statins
(n = 1,464)
P value
Study treatment group 0.964
Bivalirudin 1,555 (50.1) 734 (50.1)
Unfractionated heparin 1,551 (49.9) 730 (49.9)
Age (years) 67.2 ± 10.4 66.7 ± 9.7 0.106
Women—no. (%) 667 (21.5) 408 (27.9) \0.001
Diabetes—no. (%) 895 (28.8) 359 (24.5) 0.002
Insulin-treated—no. (%) 270 (8.7) 97 (6.6) 0.016
Arterial hypertension—no. (%) 2,836 (91.3) 1,242 (84.8) \0.001
Current smoker—no. (%) 1,401 (45.1) 623 (32.0) 0.105
Hypercholesterolemia—no. (%) 2,754 (88.7) 891 (60.9) \0.001
Stable angina—no. (%) 2,671 (86.0) 1,197 (81.8) \0.001
Unstable angina—(%) 391 (12.6) 211 (14.4) 0.088
Number of diseased coronary arteries \0.001
One vessel—no. (%) 447 (14.4) 464 (31.7)
Two vessels—no. (%) 856 (27.6) 535 (29.7)
Three vessels—no. (%) 1,803 (58.0) 565 (38.6)
Prior myocardial infarction—no. (%) 1,206 (38.8) 217 (14.8) \0.001
Prior aortocoronary bypass surgery –no. (%) 463 (14.9) 71 (4.8) \0.001
Body mass index (kg/m2) 27.6 ± 4.2 27.6 ± 4.0 0.813
Serum creatinine (mg/dl) 1.0 ± 0.3 0.9 ± 0.2 \0.001
Serum low-density lipoprotein cholestero
(mg/dl)
103.7 ± 37.1 131.2 ± 41.7 \0.001
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incidence of myocardial infarction (4.9 vs. 5.2%,
P = 0.730) compared with UFH. On the other hand,
among patients not taking statins, there was a significant
difference in the incidence of myocardial infarction
favoring UFH (4.1 vs. 7.1%, P = 0.013) which led to a
significant differences in the triple composite of ischemic
complications (death, myocardial infarction or urgent
target vessel revascularization) favoring UFH therapy (4.2
vs. 7.4% in the bivalirudin group, P = 0.010). In the non-
statin group, major bleeding remained numerically lower
with bivalirudin than with UFH (4.0 vs. 5.2%, P = 0.250).
The dependence of the statin–antithrombotic agent
interaction regarding the incidence of myocardial infarc-
tion was tested in the multivariable model investigating the
Table 2 Lesion and procedural
characteristics
Data are mean ± SD or number
of lesions (with percents in
parentheses)
Characteristic On statins (n = 5,255) Not on statins (n = 2,500) P value
Target vessel \0.001
Left main coronary artery—no. (%) 226 (4.3) 67 (2.7)
LAD coronary artery—no. (%) 1,977 (37.6) 1,098 (43.9)
Left circumflex coronary artery—no. (%) 1,347 (25.6) 643 (25.7)
Right coronary artery—no. (%) 1,579 (30.1) 679 (27.2)
Venous bypass graft—no. (%) 126 (2.4) 13 (0.5)
Complex (B2/C) lesions no. (%) 3,604 (68.6) 1,642 (65.7) 0.010
Chronic occlusions no. (%) 350 (6.7) 184 (7.4) 0.255
Lesion length (mm) 14.36 ± 8.68 14.21 ± 9.11 0.480
Vessel size (mm) 2.84 ± 0.55 2.83 ± 0.55 0.388
Diameter stenosis prior to procedure (%) 62.4 ± 15.4 64.3 ± 14.8 \0.001
Maximal balloon pressure (atm) 16 [13; 18] 14 [12; 17] \0.001
Balloon-to vessel ratio 1.10 ± 0.1 1.09 ± 0.1 0.028
Type of intervention
Drug-eluting stent no. (%) 4,570 (87.0) 2,229 (89.2) \0.001
Bare-metal stent no. (%) 291 (5.5) 145 (5.8)
Balloon angioplasty no. (%) 394 (7.5) 126 (5.0)
Length of stented segment (mm) 23.0 ± 11.1 22.4 ± 10.8 0.034
Diameter stenosis after procedure (%) 12.5 ± 10.4 12.2 ± 11.1 0.305
Table 3 Main concomitant
drug therapy at admission
Data are number of patients
(with percents in parentheses)
Characteristic On statins (n = 3,106) Not on statins (n = 1,464) P value
Aspirin 2,815 (90.6) 864 (59.0) \0.001
Clopidogrel 1,494 (48.1) 226 (15.4) \0.001
Angiotensin-converting enzyme inhibitor 1,986 (63.9) 546 (37.3) \0.001
b-blocker 2,598 (83.6) 736 (50.3) \0.001
Table 4 Primary quadruple endpoint, triple endpoint, and their components
Characteristic On statins
(n = 3,106)
Not on statins
(n = 1,464)
P value P for
interaction
Composite of death, myocardial infarction, urgent target vessel
revascularization, or major bleeding
246 (7.9) 143 (9.8) 0.036 0.05
Composite of death, myocardial infarction or urgent target
vessel revascularization
164 (5.3) 85 (5.8) 0.464 0.024
Death 5 (0.2) 2 (0.1) 0.844 0.705
Myocardial infarction 156 (5.0) 82 (5.6) 0.411 0.028
Urgent target vessel revascularization 21 (0.7) 15 (1.0) 0.213 0.466
Major bleeding 107 (3.4) 67 (4.6) 0.062 0.503
Data are number of patients (with percents in parentheses)
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independent correlates of myocardial infarction (see
‘‘Methods’’ for the variables entered into the model). The
model showed that the independent predictors of increased
risk of myocardial infarction at 30 days were: absence of
statin use at randomization (P = 0.006), use of bivalirudin
(P = 0.015), female sex (P = 0.010), unstable angina
(P = 0.023), multivessel disease (P \ 0.001). In the mul-
tivariable model, there was a significant interaction
between statin therapy and type of antithrombotic agent
(P = 0.026) in the sense that best outcomes with biva-
lirudin were achieved in patients on statin therapy before
the procedure. These P values continued to show signifi-
cance even after adjustment for concomitant drug therapy
recorded at admission.
Discussion
We describe on the basis of a post-hoc analysis a clinically
relevant influence of statins on the safety and efficacy of
antithrombotic therapy during PCI. Since these results are
based on a post-hoc analysis they must be taken with care
and regarded as hypothesis generating. These results indi-
cate that despite having a more adverse cardiovascular risk
profile, patients on statin therapy at the time of PCI had
better 30-day clinical outcomes than patients who were not
on statins. However, the principal finding of this analysis
was that statin therapy at the time of PCI was associated
with a significantly better outcome among patients
assigned to bivalirudin, primarily by reducing the fre-
quency of procedural MI. Furthermore, the known ability
of bivalirudin to reduce in-hospital major bleeding seemed
to be accentuated among patients taking statins. Since
statin therapy is pivotal in the pharmacological treatment of
patients with cardiovascular diseases, and essentially all
patients with coronary disease (and certainly those with
disease significant enough to require a PCI) ought to be on
a statin, and the use of antithrombotic therapy is mandatory
during PCI, the findings of the present study may be of
particular clinical importance.
Bivalirudin is a relatively new direct thrombin inhibitor
which has been investigated for potential pharmacody-
namic interactions with other antithrombotic and anti-
platelet drugs as part of its preclinical evaluation studies. It
was shown that bivalirudin does not have a pharmacody-
namic interaction with ticlopidine, glycoprotein IIb/IIIa
inhibitors, low molecular weight heparins or UFH [16]. In
addition, bivalirudin has been administered safely with
aspirin and clopidogrel in clinical trials [16]. Bivalirudin is
not metabolized by the cytochrome P-450 enzymatic sys-
tem and does not bind to plasma proteins other than
thrombin. Therefore, its potential for drug–drug interac-
tions is believed to be low [17].
Growing evidence is available that the treatment with
statins can lead to a significant downregulation of the
coagulation cascade, most probably as a result of decreased
tissue factor expression, which leads to reduced thrombin
generation, suggesting that these drugs might act as ‘‘weak
anticoagulants’’ [18, 19]. On the other hand, atorvastatin
resulted in a significant decrease in plasma concentrations
of antithrombin III by decreasing the biosynthetic ability of
hepatocytes [20]. Unlike bivalirudin, which is a direct
thrombin inhibitor, UFH is an indirect thrombin inhibitor
whose mechanism of action requires antithrombin III.
Deficiency in antithrombin III is known to be associated
with reduced efficacy of heparin [21].
In light of these results, future studies or retrospective
analyses of previous studies comparing UFH and biva-
lirudin during PCI ought to be performed to see if this
finding can be confirmed. Since the majority of acute
myocardial infarctions occur as a first manifestation of
coronary artery disease, it is interesting to speculate
Table 5 Primary quadruple endpoint, secondary triple endpoint and their components
On statin therapy (n = 3,106) P value Not on statin therapy
(n = 1,464)
P value
Bivalirudin
(n = 1,555)
Heparin
(n = 1,551)
Bivalirudin
(n = 734)
Heparin
(n = 730)
Composite of death, myocardial infarction, urgent
target vessel revascularization or major bleeding
111 (7.1) 135 (8.7) 0.106 79 (10.8) 64 (8.8) 0.198
Composite of death, myocardial infarction
or urgent target vessel revascularization
80 (5.1) 84 (5.4) 0.735 54 (7.4) 31 (4.2) 0.010
Death 1 (0.06) 4 (0.26) 0.178 2 (0.3) 0 (0.0) 0.158
Myocardial infarction 76 (4.9) 80 (5.2) 0.730 52 (7.1) 30 (4.1) 0.013
Urgent target vessel revascularization 10 (0.6) 11 (0.7) 0.822 9 (1.2) 6 (0.8) 0.442
Major bleeding 41 (2.6) 66 (4.3) 0.013 29 (4.0) 38 (5.2) 0.250
Data are number of patients (with percents in parentheses)
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whether a small number of patients in the Harmonizing
Outcomes with Revascularization and Stents in Acute
Myocardial Infarction (HORIZONS-AMI) trial were on
statins at time of PCI, which might explain the high rate of
acute stent thrombosis in the bivalirudin arm in the first
24 h of this trial [4].
Bivalirudin, in contrast to UFH and low molecular
weight heparin, is active against fibrin-bound thrombin by
a bivalent and reversible bond. It does not activate plate-
lets, does not bind to plasma proteins, does not cause
heparin-induced thrombocytopenia, and has linear phar-
macokinetics with a short half-life of 25 min [16]. These
pharmacologic properties suggest that bivalirudin has a
wide therapeutic range, which should translate into both
less thrombotic events and less bleeding compared with
unfractionated and low molecular weight heparins. Clinical
trials, however, failed to demonstrate a reduction in
ischemic complications with bivalirudin compared with
UFH. The novel finding of this analysis is that bivalirudin
therapy was associated with better outcomes in terms of
ischemic and bleeding complications among patients
already on statins at the time of PCI. We cannot know for
sure that this finding on post-hoc analysis is real, let alone
confirm the exact mechanism of this influence. In this
analysis, two-thirds of patients were on statins at time of
enrollment. The percentage of patients undergoing PCI
who are on statins may increase in the future due to recent
findings suggesting that even healthy individuals with low
LDL cholesterol and elevated C-reactive protein experi-
ence a marked reduction in cardiovascular morbidity and
mortality when treated with 20 mg rosuvastatin compared
to placebo [22].
The other relevant finding of this study is the confir-
mation of the previously described positive effect of pre-
procedural statin therapy on peri-procedural adverse events
and, in particular, procedural myocardial infarction [7–10].
Lack of statin therapy at the time of PCI was an indepen-
dent risk predictor for development of myocardial infarc-
tion at 30 days in our analysis as well.
In a previous analysis from the ISAR-REACT 3 trial, we
showed that bivalirudin and unfractionated heparin had
different effects on the risk of bleeding and myocardial
infarction across various subsets of patients [23]. Neither
bivalirudin nor heparin showed any specific advantage in
high-risk subsets for bleeding or myocardial infarction,
respectively. Subsets of patients who showed the greatest
reduction in the risk of bleeding with bivalirudin showed a
greater increase in the risk of myocardial infarction [23].
The present study was a post-hoc analysis of the ISAR-
REACT 3 trial and, therefore, it is subject to limitations
inherent to this type of studies. Findings of subgroup
analysis should be interpreted with caution because of the
potential for erroneous findings due to multiple testing. We
did not document the duration, type nor dose of prepro-
cedural statin therapy, which precludes any conclusions in
this regard. Nonetheless, the present analysis describes for
the first time an apparent interaction with statins which
enables bivalirudin to reduce both bleeding and ischemic
complications after PCI. There were no specific tests done
to measure the antithrombotic action of the drugs exam-
ined. This interaction should be examined in other studies.
In conclusion, there appears to be an interaction between
statin therapy before PCI and the antithrombotic therapy
(bivalirudin) during the procedure. Statins also appeared to
have had a favorable effect on the incidence of post-pro-
cedural myocardial infarction, which would justify their
initiation before PCI regardless of which antithrombotic is
used, if possible.
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